Well at least you didn't buy in at the high of $54 in 2000. It was followed buy a dble top of $32 and continued downward to $1.07 last March. If that didn't make you sell in 14 yrs why would $1.98?
"The Phase 1 trial is a two-month, open-label study in approximately 30 patients at 15 to 20 clinical sites around the United States. The trial is designed to assess the safety and tolerability of topical ocular PAN-90806 at three dosage strengths in patients with active, subfoveal choroidal neovascularization associated with neovascular AMD. PanOptica expects data readout by the end of 2014"
They should have phase 1 results about the same time as Squalamines's phase 2 are due.
FDA just approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes. Tanzeum will carry a warning on its label that tumors of the thyroid gland were observed in rodent studies. I guess that's okay by the FDA
His career was cut short when his parents left Burbank for Philly. Larry Mondello for prez! Maybe we should start a petition?
I agree he maybe 'overcompensated' but name me one American CEO that isn't...most CEO's average $11.5mil/annually which is 331x what the average American worker makes, 750 x the lowest paid workers. And yet they all balk at raising the min. wage. Unless you're a beaver eating wood fiber that ain't any sustainable system.
I just hate being in any equity with such thin liquidity when macro market sentiment has become so bearish. Leaves any equity vulnerable to shorting, naked or legit and HFT take downs.
....and we all know naked shorts don't cover cause they never really existed in the first place. My broker doesn't allow shorting this equity so it must be mainly all larger hedge funds playing the SP.
Nobody will know for sure until interim results are given...hopefully in a company PR this time. Although the wanky financing deal that went down cutting SP in half and scaring off new buyers, if not for those lightening up from the top, once good data is released the SP will take out $20 in a flash. OHRP has a high relative value rating meaning it quickly recovers and a very low beta meaning it's independent of market movement. With good to great data we're golden.
Did you wake up on the rright side of the bed this morning?
...if in fact he was being treated with Imetelstat for his MM(incurable) I'm sure he'd be more than willing to help bring this to the public's attention. The MM portion of clinical testing was subjected to the FDA's complete hold.
25mil shorts...they'll make great rocket fuel when the FDA lifts the hold.
Last hold GERN had lasted 2 weeks. We're into week 4 on this one.
sheep need to be herded. Monkeys are independent brokers that operate in troops. Ever been to India?
I beg to differ but I believe it's the other way around, Monkeys raid the fruit stand and bfr. you know it the rest of us are in the dog house with nothing left to eat.
I like to say you r right but that's what I thought a month ago when I bought more down here Mar 17 @1.78 bfr this technical crossover was realized. The very next day the Seeking Alpha article triggered a nice pop to $ 2.50.
How are you at writing articles?
just that it triggers technical traders to further short a stock. 60% drop was unforeseen unless one had FDA knowledge beforehand. $1.50/share is what GERN has in the bank. IMET is worth $.30 by current market sentiment, yet it has several CR successes. JAK2 has had none and yet the SP is $42 down from $70
....a very bearish technical. Selling vol has finally dried up which is good. May want to pick up more if we continue down. INCY has only JAK2 which is JAK-all really.
Social psychological sentiment when taped into properly can move mountains. Critter karma..."FDA take down that hold"
CMRX; recently popular sentiment support stirred up by the parents of a boy with bone marrow complications who was turned down under compassionate use considerations for CMRX's antiviral. They got a lot of on-line support for their cause to use the drug and eventually Josh, facing certain death, was treated and moved from intensive care to recovery. The company eventually fired their CEO following his decision initially not to allow the emergency use in this case citing expense restrictions.(btw his name was Mooch) The company SP which tanked on the CEO's initial decision not to allow use of the drug, soon rallied on the reversed decision. The boy recovered. I always like happy endings.
Now the good DR T needs to rip that scarlet letter off of GERN and get her named cleared once and for all.